TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28130349

Group type: EXPERIMENTAL
Intervention: Nerve fibre layer haemorrhages
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cotton wool spots
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Exudates
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Pseudodrusen
Number of subjects: 133
Study: 25785804

Group type: COMPARATOR
Intervention: Alcohol consumption (target blood alcohol concentration = .08%)
Number of subjects: 215
Study: 23583458

Group type: EXPERIMENTAL
Intervention: IV aminophylline 3 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV doxapram 1 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal IV saline (control)
Number of subjects: 90
Study: 21425378

Group type: EXPERIMENTAL
Intervention: Chicory coffee (300 mL daily for 1 week)
Number of subjects: 27
Study: 18005369

Group type: EXPERIMENTAL
Intervention: Cognitive self-therapy (CST)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study: 16616650

Group type: EXPERIMENTAL
Intervention: 50% O2 in air
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50% N2O
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 36
Study: 12562375

Group type: EXPERIMENTAL
Intervention: Removable implant overdentures
Number of subjects: 13

Group type: COMPARATOR
Intervention: Fixed prostheses
Number of subjects: 13
Study: 10982198

Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-40 mg)
Number of subjects: 236
Study: 8973920

Group type: EXPERIMENTAL
Intervention: 12-week culture-specific dietary intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Distribution of health-related pamphlets
Number of subjects: 38
Study: 1581012

Group type: EXPERIMENTAL
Intervention: Captopril (25 to 50 mg, twice daily for 8 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 to 100 mg, twice daily for 8 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 to 25 mg, twice daily for 8 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2417649

Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29514649

Group type: EXPERIMENTAL
Intervention: Usual Care + Moral Reconation Therapy (MRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 27687360

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dexamethasone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraoperative superhydration of lactated Ringer's solution (30 mL/kg per fasting time)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone and intraoperative superhydration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexamethasone group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Superhydration group
Number of subjects: 120
Study: 24770699

Group type: EXPERIMENTAL
Intervention: 10‐min brisk walking 1×/week (n = 10)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10‐min brisk walking 3×/week (n = 10)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 30‐min brisk walking 3×/week (n = 18)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 60‐min brisk walking 3×/week (n = 10)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 30‐min running 3×/week (n = 14)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 72
Study: 22272945

Group type: EXPERIMENTAL
Intervention: Custom-made mouthguard (CM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Boil-and-bite mouthguard (O-Flow™ Max Under Armour®) (UA)
Number of subjects: 18
Study: 20397964

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem (Edluar) 10 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral zolpidem (Ambien) 10 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 70
Study: 18415895

Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cytotoxic agents with monoclonal antibodies
Number of subjects: 0
Study: 15976585

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (continuous wear)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (daily wear)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (continuous wear)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (daily wear)
Number of subjects: 45
Study: 15041080

Group type: EXPERIMENTAL
Intervention: BVM (bleomycin, vincristine, methotrexate)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BVM and cisplatin
Number of subjects: 38

Group type: COMPARATOR
Intervention: No cisplatin (BVM)
Number of subjects: 38
Study: 11578917

Group type: EXPERIMENTAL
Intervention: Radical gastrectomy and regional lymphadenectomy (Japan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard gastrectomy (West)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant and neoadjuvant treatment regimens (Japan and West)
Number of subjects: 0
Study: 9258576

Group type: EXPERIMENTAL
Intervention: Progesterone therapy (oral administration during the second luteal phase)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion (3% saline solution administered on an early follicular and a late luteal phase day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Follicular phase (control phase for each subject)
Number of subjects: 6
Study: 8298782

Group type: EXPERIMENTAL
Intervention: Arm splints (postoperative period)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No arm splints (postoperative period)
Number of subjects: 46
Study: 3638441

Group type: EXPERIMENTAL
Intervention: Family-based health behavior change intervention, 12 weekly sessions and six maintenance sessions over nine months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 0
Study: 31595955

Group type: EXPERIMENTAL
Intervention: Growth measures (standardized weight, length/height, body mass index) during ages 6.5-11.5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Growth measures during gestation and the first year of life
Number of subjects: 0
Study: 30031383

Group type: EXPERIMENTAL
Intervention: Boost camp intervention (14 lessons over 2 days, followed by Booster sessions)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 300
Study: 27051376

Group type: EXPERIMENTAL
Intervention: Bonfils fiberoptic scope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 24754044

Group type: EXPERIMENTAL
Intervention: Exercise immediately before sexual activity (3×/week)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Regular sexual activity (3×/week)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise (3×/week)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Regular sexual activity and exercise
Number of subjects: 52
Study: 22551813

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20463094

Group type: EXPERIMENTAL
Intervention: Two tablets/week increase in l-T(4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Three tablets/week increase in l-T(4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monitoring TSH every 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trimester-specific TSH lower reference range of 0.1 mIU/liter
Number of subjects: 60
Study: 18166547

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release 2 mg/day
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release 3 mg/day
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release 4 mg/day
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (all doses)
Number of subjects: 345
Study: 15923670

Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2b (100 mug weekly) combined with daily lamivudine (100 mg)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Peg-interferon alpha-2b (100 mug weekly) combined with placebo
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Host induced flare
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Virus induced flare
Number of subjects: 266
Study: 12952117

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 2 sprays per nostril, twice daily
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray plus loratadine 10 mg daily
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily plus placebo nasal spray
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo (saline) nasal spray
Number of subjects: 428
Study: 10632736

Group type: EXPERIMENTAL
Intervention: Desmopressin after aspirin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin after placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second dose of desmopressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall effect of desmopressin
Number of subjects: 0
Study: 8649552

Group type: EXPERIMENTAL
Intervention: Tacrine with estrogen replacement therapy (ERT)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Tacrine without estrogen replacement therapy (ERT)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 1622163

Group type: EXPERIMENTAL
Intervention: 2-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 4-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Number of subjects: 163
Study: 6085099

Group type: EXPERIMENTAL
Intervention: Alcoholic povidone-iodine ('Betadine') alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alcoholic povidone-iodine ('Betadine') covered with an incise drape ('Steri-Drape')
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Iodine-containing incise drape ('Ioban') alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 30924513

Group type: EXPERIMENTAL
Intervention: Labor and delivery education program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard nursing guidance
Number of subjects: 151
Study: 28727629

Group type: EXPERIMENTAL
Intervention: Automated inpatient split-dose bowel preparation system
Number of subjects: 969
Study: 26505139

Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback
Number of subjects: 44

Group type: COMPARATOR
Intervention: No-feedback control
Number of subjects: 44
Study: 25439694

Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg intravenously, six injections, one every 4 weeks)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study: 22527350

Group type: EXPERIMENTAL
Intervention: Methantheline (100 mg) as immediate-release coated tablets (IR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methantheline (100 mg) in watery solution (SOL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atropine (1.0 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 12
Study: 21309495

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg remifentanil (group R)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg remifentanil with venous retention for 30 s (group R')
Number of subjects: 96

Group type: COMPARATOR
Intervention: 2 ml saline (placebo group)
Number of subjects: 96
Study: 17698746

Group type: EXPERIMENTAL
Intervention: Group 1 (SD <= 2)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Group 2 (SD > 2)
Number of subjects: 408
Study: 16243997

Group type: EXPERIMENTAL
Intervention: Clonidine (2 microg/kg oral)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12199431

Group type: EXPERIMENTAL
Intervention: Lincomycin hydrochloride (220 ppm in feed from day 71 to day 91)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vaccination against Mycoplasma hyopneumoniae (at four and 28 days of age)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both lincomycin hydrochloride and vaccination
Number of subjects: 61

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 61
Study: 10420905

Group type: EXPERIMENTAL
Intervention: PGE1 (10, 20, or 40 ng/kg/min)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PGE1 (20 ng/kg/min)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 7776458

Group type: EXPERIMENTAL
Intervention: Recombinant human tumor necrosis factor (200, 400, and 1,000 micrograms) given intravesically weekly for 11 weeks (dwell time 2 hours)
Number of subjects: 9
Study: 2186066

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PMR plus cognitive therapy (PMR + Cog)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pseudomeditation (placebo control)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continued headache monitoring (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PMR and PMR + Cog (combined)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PMR + Cog
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PMR
Number of subjects: 66
Study: 378986

Group type: EXPERIMENTAL
Intervention: Lithium in combination with a thiazide diuretic
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lithium in combination with a low sodium diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lithium alone
Number of subjects: 27
Study: 30653416

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham (mock IPC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study: 28185444

Group type: EXPERIMENTAL
Intervention: Cis-palmitoleic acid (720 mg/day for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25928427

Group type: EXPERIMENTAL
Intervention: Feedback intervention (n = 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (assessment-only, n = 13)
Number of subjects: 30
Study: 24115080

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 97
Study: 21871373

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 2.5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (mean dose 3 mg)
Number of subjects: 40
Study: 19421075

Group type: EXPERIMENTAL
Intervention: 3-day diary
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-day diary
Number of subjects: 0
Study: 17362248

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15226521

Group type: EXPERIMENTAL
Intervention: Held by a parent (HLD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Supine position (SUP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 2-month-old infants
Number of subjects: 106
Study: 11561920

Group type: EXPERIMENTAL
Intervention: Midazolam injection prior to study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no midazolam injection)
Number of subjects: 0
Study: 10802404

Group type: EXPERIMENTAL
Intervention: 1.25 mg/day tibolone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day tibolone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 8921820

Group type: EXPERIMENTAL
Intervention: GnRH (10-100 micrograms)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GnRH (10-25 micrograms)
Number of subjects: 19
Study: 1653141

Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan (20 mg plus 20 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 6811034

Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythrocyte homogenates from flushers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythrocyte homogenates from non-flushers
Number of subjects: 0
Study: 30511312

Group type: EXPERIMENTAL
Intervention: Laparoscopic percutaneous inguinal ring suturing (PIRS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open modified Marcy technique
Number of subjects: 32
Study: 29519502

Group type: EXPERIMENTAL
Intervention: 3 mg NGM282
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 6 mg NGM282
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: NGM282 (both doses combined)
Number of subjects: 82
Study: 27395805

Group type: EXPERIMENTAL
Intervention: Intensive ERP-based treatment (1 session psychoeducation, 2 sessions ERP plus e-therapy maintenance)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6-month follow-up
Number of subjects: 10
Study: 24955448

Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: 14-day sequential therapy
Number of subjects: 184
Study: 21659900

Group type: EXPERIMENTAL
Intervention: RT + diet (n = 5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: diet (n = 4)
Number of subjects: 9
Study: 20189560

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17611252

Group type: EXPERIMENTAL
Intervention: 25 degrees back-up position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of positions
Number of subjects: 40
Study: 16286463

Group type: EXPERIMENTAL
Intervention: Foot chill
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 180
Study: 12040992

Group type: EXPERIMENTAL
Intervention: Instructions in ultrasound pressure application (Group 1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No instructions in ultrasound pressure application (Group 2)
Number of subjects: 65
Study: 10768024

Group type: EXPERIMENTAL
Intervention: Kinetic response Arabic letter distance visual acuity test chart
Number of subjects: 0
Study: 7593442

Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST) 0.1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST) 0.05 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST) 0.01 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control saline injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST)
Number of subjects: 12
Study: 2367197

Group type: EXPERIMENTAL
Intervention: 30 degrees elevated position
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 70 degrees elevated position
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chair position
Number of subjects: 64

Group type: COMPARATOR
Intervention: Flat bed position
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sidelying position
Number of subjects: 64
Study: 30281074

Group type: EXPERIMENTAL
Intervention: Antimicrobial catheter lock solution containing trimethoprim 5 mg/mL, ethanol 25%, and Ca‐EDTA 3% (IMD)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Heparin 5000 U/mL (active control heparin, ACH)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Antimicrobial catheter lock solution (IMD)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Heparin 5000 U/mL (ACH)
Number of subjects: 270
Study: 29624592

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine CVD 103-HgR (5 × 10^8 CFU)
Number of subjects: 46
Study: 27053641

Group type: EXPERIMENTAL
Intervention: Active PES
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham PES
Number of subjects: 36
Study: 24710336

Group type: EXPERIMENTAL
Intervention: Azilsartan (20-40 mg once daily)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Candesartan (8-12 mg once daily)
Number of subjects: 548
Study: 21684040

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 minutes, 1 mA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 20550489

Group type: EXPERIMENTAL
Intervention: Preserved topical levofloxacin (0.01% benzododecinium bromide)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Unpreserved topical levofloxacin
Number of subjects: 62
Study: 17502775

Group type: EXPERIMENTAL
Intervention: Aripiprazole monotherapy (30 mg once daily) for 14 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Coadministration of carbamazepine with aripiprazole
Number of subjects: 9
Study: 15994985

Group type: EXPERIMENTAL
Intervention: Reports of randomized controlled trials (RCTs)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Reports of controlled clinical trials (CCTs)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Trial reports stating ethical approval obtained
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Trial reports indicating informed consent obtained
Number of subjects: 155
Study: 12168276

Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV) during Fiberoptic Bronchoscopy (FB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no HV) during Fiberoptic Bronchoscopy (FB)
Number of subjects: 34
Study: 9738725

Group type: EXPERIMENTAL
Intervention: LAC formula (lactose as the sole carbohydrate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LAC formula
Number of subjects: 6

Group type: COMPARATOR
Intervention: SC formula (standard preterm formula with 50% lactose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: SC formula
Number of subjects: 6
Study: 8570447

Group type: EXPERIMENTAL
Intervention: Correctly placed IO needles (intramedullary)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Incorrectly placed IO needles (extramedullary)
Number of subjects: 12